Female/71 |
Chronic lymphocytic leukemia, acquired hypo-gammaglobulinemia |
105 days |
On days 49 and 70 post-symptom onset |
Symptoms were not developed along viral infection. Viral load was controlled after day 70 by convalescent plasma |
3939 Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183:1901-1912.e9.
|
Male/61 |
Liver transplant, immunosuppressive therapy for 11 years |
52 days |
- |
Mild symptoms and lung damage. Transient suspension of immunosuppressive drugs and treatment with lopinavir/ritonavir |
4040 Wei L, Liu B, Zhao Y, Chen Z. Prolonged shedding of SARSCoV-2 in an elderly liver transplant patient infected by COVID19: a case report. Ann Palliat Med. 2020. apm-20-996.
|
Male/62 |
Heart transplant, immunosuppressive regimen |
35 days |
On days18 and 21 post-symptom onset |
Mild symptoms. Immunosuppressive therapy was maintained. Hydroxychloroquine was administered from day 7-14 up to end of symptoms |
4141 Decker A, Welzel M, Laubner K, et al. Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation. Am J Transplant. 2020;20:3239- 45.
|
Female/9 months old |
Myelomonocytic leukemia with stem cell transplant |
At least 4 months |
- |
Symptoms and lung damage were developed after 45 days from first positive SARS-CoV-2 RT-PCR. Convalescent plasma improved lung lesions |
4242 Balashov D, Trakhtman P, Livshits A, et al. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation. Transfus Apher Sci. 2021;60:102983.
|
Male/47 |
Follicular lymphoma in remission. Immunocompromised status. |
55-59 days |
On day 59 after first positive test |
Mild symptoms and lung damage. RT-PCR negativization on day 65 |
4343 Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. 2021;27:387-9.
|
Male/49 |
Mixed connective tissue disease, rheumatoid arthritis, and systemic lupus. Immunosuppressive therapy and acquired humoral deficiency |
60 days |
- |
Development of respiratory distress after a week from first RT-PCR positive test.Treatment with IVIG, hydroxychloroquine and azithromycin |
4444 Schend J, Daniels P, Sanan N, Tcheurekdjian H, Hostoffer R. Clinical observation of COVID-19 in a patient with an acquired humoral deficiency secondary to chemotherapeutic agents. Allergy Rhinol (Providence). 2020;11:2152656720978764.
|
Female/63 |
No Hodgkin lymphoma in remission. Treatment with anti-CD20 MAb was suspended 37 days previous to symptoms onset |
At least 74 days |
- |
Undetectable IgG on day 75 post-symptom onset. Hospitalization on day 88 and treatment with convalescent plasma that resolved symptoms |
4545 Moore JL, Ganapathiraju PV, Kurtz CP, Wainscoat B. A 63-year-old woman with a history of non-hodgkin lymphoma with persistent SARS-CoV-2 infection who was seronegative and treated with convalescent plasma. Am J Case Rep. 2020;21:e927812.
|
Male/60
|
Mantle cell lymphoma. Treatment with anti-CD20, prednisone, cyclophosphamide and doxorubicin |
156 days |
Along 119 days |
Genome sequencing of nine viral isolates, suggested within-host evolution and no reinfection |
4646 Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223:23-7.
|
Female/78 |
Type 2 diabetes and hypertension. Complications of thyroidectomy 23 years ago that required tracheostomy |
At least 47 days |
- |
Supplemental oxygen was required. Discharge on day 55 post-symptom onset |
4747 McKie AM, Jones TPW, Sykes C. Prolonged viral shedding in an immunocompetent patient with COVID-19. BMJ Case Rep. 2020;13:e237357.
|
Male/45 |
Antiphospholipid syndrome complicated by diffuse alveolar hemorrhage. Anticoagulation therapy and glucocorticoids |
151 days |
- |
Initially, patient developed fever. Complications avoid COVID-19 resolution. Analysis of postmortem tissue revealed high viral loads in lungs and spleen. Viral genome sequencing was consistent with persistent infection |
4848 Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:2291-3.
|